CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
sicklecellanemianews22h
SCD patients can access Casgevy via England’s public health system
Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...
Reprogramming compromised immune cells to fight cancer
Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to act against tumors, ...
chromatographyonline20h
Advancing Gene Therapy: Enzyme Selection For Effective RNA Oligonucleotide Mapping
New gene therapy modalities, such as CRISPR guide RNA (single guide ribonucleic acid [sgRNA]) and messenger RNA (mRNA), ...